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Abstract: Probiotics are defined as live microorganisms that when administered in adequate
amounts confer a health benefit to the host. Their positive supplementation outcomes on several
gastrointestinal disorders are well defined. Nevertheless, their actions are not limited to the gut,
but may also impart their beneficial effects at distant sites and organs. In this regard, in this review
article we: (i) comprehensively describe the main mechanisms of action of probiotics at distant sites,
including bones, skin, and brain; (ii) critically present their therapeutic potential against bone, skin,
and neuronal diseases (e.g., osteoporosis, non-healing wounds and autoimmune skin illnesses, mood,
behavior, memory, and cognitive impairments); (iii) address the current gaps in the preclinical and
clinical research; and (iv) indicate new research directions and suggest future investigations.
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1. Introduction
Probiotics are defined as live microorganisms with health promoting properties. Although,
the term “probiotics” was introduced by Lilly and Stillwell in 1965, Elie Metchnikoff, the Russian
immunologist and Nobel Laureate in Medicine, was the first to describe their beneficial effects more
than a century ago. Metchnikoff linked regular consumption of yogurt to the delay of the aging
process and the promotion of longevity. His theory, presented in his book “The Prolongation of Life”,
published in 1907, stated that putrefactive bacteria present in the gut release toxins and other harmful
substances to the host. Administration of host-friendly bacteria found in yogurt could counteract this
action, restore intestinal balance, and enhance human health. Nowadays, FAO and WHO (Food and
Agriculture Organization of the United Nations and the World Health Organization) define probiotics
as “live microorganisms that, when administered in adequate amounts, confer a health benefit on the
host” [1].
A plethora of studies have demonstrated the positive outcomes of probiotic supplementation on
several gastrointestinal disorders, such as antibiotics-associated diarrhea, irritable bowel syndrome,
necrotizing enterocolitis, ulcerative colitis, lactose intolerance, and colorectal cancer [2]. Several articles
reviewed their mechanisms of action, which include modulation of the immune system, induction of
anti-inflammatory and anti-oxidant responses, competitive pathogen exclusion, as well as production
of anti-microbial substances [3,4]. Additionally, probiotics could exert anti-proliferative effects in colon
cancer cells by inducing apoptosis and cell-cycle arrest [5,6].
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There is growing evidence that human microbiota can exert effects at sites quite distant from
the niches in which they reside. For instance, it was shown that gut bacteria can affect memory and
anxiety of animal models [7]. Interestingly, low microbiota diversity in the gut has been associated
with increased asthma at school age [8]. In this regard, probiotic action is not limited to the gut, but
also imparts their beneficial effects at distant sites and organs. Thushara et al., reviewed experimental
and clinical studies of probiotic action against cardiovascular disorders, and an update of their effects
on metabolic diseases was provided by Aggarwal et al. [9,10]. Moreover, it has been demonstrated that
probiotic consumption results in production of anti-inflammatory agents that promote bone health
and integrity and protect against primary (estrogen-deficiency) and secondary osteoporosis [11].
Similarly, probiotics have also been tested for their wound-healing abilities, protection against
UV-induced photodamage, and also for alleviation of symptoms in skin diseases, such as dermatitis and
psoriasis [12]. One of the most exciting research areas is their potential functional impact on the nervous
system and neurological diseases. Studies in animal models have shown that consumption of probiotics
can lead to decreased rate of stress- and anxiety-related symptoms [13]. Furthermore, probiotics have
been documented in preclinical studies to suppress pro-inflammatory and oxidative damage responses
in the brain, and thus, minimize the symptoms of neurodegenerative and demyelinating diseases [14].
However, as clinical evidence that supports probiotic action at distant sites is limited, no specific
recommendations and medical guidelines for appropriate administration are available [15]. In this
vein, the aims of this review are: (i) to present the main mechanisms of action of probiotics at distant
sites, including bones, skin, and brain; (ii) to comprehensively describe and evaluate their therapeutic
potential against bone, skin, and neuronal disorders (e.g., osteoporosis, non-healing wounds and
autoimmune skin illnesses, mood, behavior, memory, and cognitive impairments); (iii) to address the
current gaps in the preclinical and clinical research; and (iv) to indicate new research directions and
suggest future investigations.
2. Probiotics and Bone Diseases
Bone formation is a complex process that requires the integration of the immune, hormonal,
and neuronal systems. Hormone-associated bone damage, such as primary osteoporosis, as well as
autoimmune diseases of the bones, including rheumatoid arthritis, are directly linked to improperly
regulated inflammatory responses. Indeed, inflammation is detrimental to bone integrity, as it induces
the production of matrix and cartilage degrading enzymes from chondrocytes and synoviocytes.
Evidently, approaches targeting inflammation could be promising in managing bone disorders. In this
context, probiotics with anti-inflammatory potential may induce the production of immunosuppressant
cytokines, which activate the regulatory T-lymphocyte (Treg) population and reduce the formation of
osteoclasts, resulting in the protection of bone integrity [16].
2.1. Sex-steroid-Associated Bone Loss—Primary Osteoporosis
Sex-steroid-associated bone loss is caused by hormonal and immunological imbalances. Primary
osteoporosis represents the most common sex-steroid-associated bone disease. It is characterized by
estrogen deficiency, which impairs cellular calcium uptake, weakens the gut barrier, and consequently
causes increased permeability, which leads to endotoxemia and overactivation of immune responses.
As a result, high levels of pro-inflammatory and osteoclastogenic cytokines are released in the
gut lumen and the bone marrow, causing trabecular bone loss [17]. Probiotics counteract the
detrimental effects of the hormonal deficit in various ways, as shown by in vitro and in vivo
studies. Lactobacillus helveticus (LBK-16H) milk fermented products, isoleucyl-prolyl-proline (IPP)
and valyl-prolyl-proline (VPP), were shown to promote osteoblastic bone formation and intracellular
calcium accumulation in mouse osteoblast cells [18]. In addition, L. helveticus fermented milk prevented
bone loss by decreasing bone turnover and increasing the bone mineral density in ovariectomized
(OVX) rats [19]. Probiotic supplementation in ovariectomized female mice reversed cortical bone loss
by decreasing CD4+T cell counts and the release of anti-inflammatory factors, such as tumor necrosis
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factor-α (TNF-α) and interleukin-1β (IL-1β), whilst increasing the production of osteoprotegerin,
an important regulator of osteoclast development and function [20]. Anti-osteoclastogenic effects
were also induced in rats fed with a diet rich in lipids after the consumption of B. longum fermented
broccoli [21]. Moreover, the probiotic strain L. reuteri ATCC 6475 suppressed the expression of
pro-inflammatory and pro-osteoclastogenic cytokines locally and in the bone marrow in ovariectomized
mice [22]. Similarly, L. rhamnosus GG (LGG) decreased local and systemic inflammation and affected
positively gut barrier function, thus protecting female sex-steroid deficient C57BL6/J mice against
bone loss [23].
Other studies examined the morphological and biomechanical changes in bones of animal models
after probiotic consumption. The animal bones were harvested post-mortem and examined using
plasma emission spectrophotometry, fracture tests, and X-ray microcomputed tomography. In this
context, L. paracasei subsp. paracasei NTU 101 and L. plantarum NTU 102 fermented soy milk increased
bone density and thickness in female BALB/c ovariectomized mice. Of note, fermentation increased
milk levels of calcium, vitamin D3, and isoflavone levels [24]. Similarly, B. longum alone, or in
combination with yacon flour, a food with prebiotic potential, increased bone mineral content and
strength in male Wistar rats compared to control rats. In addition, the combination of the two
interventions resulted in elevated concentration of the propionic acid, while B. longum alone increased
butyrate levels in the cecum [25]. It is well-established that short chain fatty acids (SCFAs), such as
propionic acid and butyrate, maintain the integrity of the gut epithelium function by upregulating
transcription of tight junction proteins and by limiting mucosal inflammatory responses [26,27].
Concomitantly, SCFAs promote bone health by inhibiting the differentiation of osteoclasts and
decelerating bone resorption, as shown by in vitro and in vivo experiments [28].
Preliminary results from clinical studies have confirmed the beneficial effects of probiotics on
bone diseases (Table 1). In a recent clinical trial, fifty osteopenic postmenopausal women over the age
of 50 consumed GeriLact, a mixture of seven probiotic strains, for six months. Probiotic consumption
influenced total hip and blood markers of bone turnover and resorption, including serum bone-specific
alkaline phosphatase, osteocalcin, collagen type 1 cross-linked C-telopeptide, parathyroid hormone,
vitamin D, and the proinflammatory cytokines, TNF-α and IL-1β. The overall positive result of
GeriLact consumption was the deceleration of bone turnover rate [29]. In another study, healthy
menopausal women who consumed tablets containing the probiotic stain Bacillus subtilis C-3102
exhibited increased bone mineral density accompanied with distinctive microbiological shifts in fecal
samples. In particular, the Fuseobacterium population was significantly decreased, while species from
the genus Bifidobacterium were found in greater concentrations. These changes in gut populations
were attributed to reduced pro-inflammatory responses and inhibited osteoclast activity, ultimately
favoring bone integrity and promoting the preventative potential of B. subtilis C-3102 on bone loss [30].
Nonetheless, further studies are required to validate the beneficial effects of this strain on osteoporotic
patients. Finally, osteoporotic males that consumed kefir, a probiotic-enriched fermented dairy product,
had increased femoral neck bone mineral density [31] (Table 1).
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Table 1. Summary of clinical trials investigating the beneficial effects of probiotics on bone diseases.
Probiotic Strain Type of Study Regimen Findings Clinical Outcomes Reference
Kefir-fermented milk
40 osteoporosis patients
participated in a controlled,
parallel, double-blind
intervention study
Consumption of 1600 mg kefir-fermented
milk per day for 6 months
↑serum PTH
↑β-CTX
↑Osteocalcin
Increased femoral neck
bone mineral density [31]
L. casei Shirota
537 knee osteoarthritis patients
participated in a double-blind,
placebo-controlled trial
Oral administration, daily dose of
6 × 109 CFU for 6 months
↓WOMAC
↓VAS score
↓hs-CRP
Inflammation decrease [32]
L. casei Shirota
417 elderly patients with acute
distal radius fracture participated
in a double-blind,
placebo-controlled trial
Oral administration, daily dose of 1.2 ×
1010 CFU for 6 months
↓DASH score
↓pain VAS
↓CRPS score
Faster fracture
rehabilitation [33]
L. acidophilus,
L. casei,
B. bifidum
60 RA patients participated in a
randomized, double-blind,
placebo-controlled trial
One capsule daily for 8 weeks (viable and
freeze-dried strains at 2 × 109 CFU/g
each)
↓hs-CRP
↓DAS-28
↓Insulin
↓HOMA-B
Inflammation decrease [34]
L. casei 01
60 female RA patients
participated in a randomized
double-blind clinical trial
One capsule daily for 8 weeks (108
CFU/capsule)
↓hs-CRP
↓DAS-28
↓IL-12
↓TNF-α
Inflammation decrease [35]
PTH: parathyroid hormone; β-CTX: β C-terminal telopeptide of type I collagen; CFU: colony forming units; WOMAC: Western Ontario and McMaster Universities osteoarthritis index;
VAS: visual analogue scale; hs-CRP: highly-sensitive C-reactive protein; DASH: disabilities of the arm, shoulder and hand; CRPS: complex regional pain syndrome; RA: rheumatoid
arthritis; DAS-28: disease activity score-28; HOMA-B: homeostasis model of assessment-estimated insulin resistance; IL-12: inteleukin-12; TNF-α: tumor necrosis factor-α (↑: upregulation,
↓: downregulationPage: 4).
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2.2. Autoimmune Diseases of the Bone
Rheumatoid arthritis (RA) is a multifactorial chronic autoimmune inflammatory disease. Its onset
is often linked with exposure to various enteropathogens. Post-infection, antigenic cross-reactivity
and the hyperproduction of inflammatory cytokines induce autoimmunity that leads to osteoclastic
bone resorption and low bone mineral density. In addition, RA and inflammatory bowel disease
(IBD) are oftentimes co-morbid. IBD-induced inflammation loosens the gut barrier and results
in mass presentation of antigens to the intestinal immune system. It has been reported that
probiotic supplementation could be effective in preventing and alleviating autoimmune bone disease.
In particular, mice with collagen-induced arthritis (CIA) are widely used as experimental models of
RA. CIA mice that were fed or inoculated with L. helveticus SBT2171 had dampened immune responses,
ultimately resulting in alleviation of arthritis. This was mainly due to the decrease in auto-reactive
B and T lymphocytes in draining lymph nodes, serum type II collagen (CII)-specific antibodies, and
inflammatory cytokines [36]. Similarly, mice that were fed with a mixture of probiotics, zinc, and
coenzyme Q10 exhibited alleviated arthritis symptoms that were attributed to the downregulation of
proinflammatory cytokines [37]. However, a few clinical studies have yielded the expected results so
far (Table 1). In a recent study, the use of probiotics in patients with knee osteoarthritis was investigated.
In this group of patients, daily consumption of skimmed milk containing L. casei Shirota demonstrated
lower scores in the Western Ontario and McMaster Universities Osteoarthritis Index and Visual Analog
Scale tests, while serum high-sensitivity C-reactive protein (hs-CRP), an indicator of musculoskeletal
inflammation, was decreased [32]. Interestingly, the researchers had previously established that L. casei
Shirota accelerated healing of distal radius fractures [33]. Additionally, Zamani et al. showed that
administration of a probiotic mixture consisting of L. acidophilus, L. casei, and B. bifidum normalized the
levels of inflammatory markers and eased the clinical manifestations of RA [34]. In the same manner,
women suffering from RA that consumed L. casei 01 daily for two weeks experienced improved drug
responsiveness to disease-modifying anti-rheumatic drugs [35]. Nevertheless, further preclinical and
clinical studies are required to delineate the health promoting effects of probiotics and the underlying
molecular mechanisms related to specific bone diseases.
3. Probiotics and Skin Health
The interplay of hormonal, neuronal, and inflammatory signaling has a great impact on skin
health. Psychological distress alters skin physiology by stimulating pro-inflammatory responses [38].
Indeed, acne, a common skin condition among adolescents and young adults, is correlated with
neurogenic skin inflammation, which alters the functionality and survival of mast cells and induces the
production of vasodilatory and proinflammatory factors. In addition, psychological stress upregulates
secretion of prolactin, which in turn determines keratinocyte proliferation and sebum production
by sebaceous glands [39]. Similarly, the onset of autoimmune skin diseases, such as psoriasis, and
of allergic disorders, such as atopic dermatitis, is correlated to chronic inflammation and mast cell
degranulation. The underlying, prolonged inflammatory responses induce keratinocyte apoptosis,
contributing to the distinctive skin manifestations of these disorders. Current therapeutic approaches
are either strenuous for the patient or have little effect. Probiotic bacteria with anti-inflammatory
properties have the potential to be of therapeutic benefit for people suffering from neurogenic skin
inflammation or autoimmune skin diseases. Nevertheless, more clinical evidence is needed to support
their routine use in medical practice. Likewise, probiotics that protect the keratinocytes from oxidative
stress or that induce skin re-epithelization could be of invaluable importance towards non-healing
wounds. In addition, it has been shown that specific probiotic strains prevent skin aging by reversing
photodamage. This finding highlights the potential of probiotics as supporting agents in skin health.
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3.1. Neurogenic Skin Inflammation, Acne Rosacea, and Acne Vulgaris
Neurogenic skin inflammation arises from stress-induced over-expression of inflammatory
cytokines and affects hair and skin by inhibiting hair growth and keratinocyte proliferation, respectively.
It has been demonstrated that L. reuteri BM36301 supplementation on female C57BL/6 mice resulted
in active hair growth, counteracted the hair follicle regression, and halted the recruitment of activated
macrophages and dendritic cells perifollicularly [40]. In another study, investigators using an ex vivo
skin explant model and showed that cell-free extract (CFE) from B. longum exhibited anti-inflammatory
properties and protected skin from physical and chemical aggression [41].
Changes in skin microbiota composition and simultaneous bacterial overgrowth in the small
intestine are quite common among individuals with acne rosacea. Indeed, Propiobacterium acnes
overpopulation has been recorded in acne patients. Antibiotics targeting P. acnes are conventionally
used to resolve acne. Alternatively, it has been reported that enhancement of Staphylococcus epidermidis
skin population excludes P. acnes from sebaceous hair follicles. The antimicrobial effects of S. epidermidis
are attributed to the production of SCFAs that exert direct microbicidal actions against P. acnes [42].
Interestingly, stimulation of S. epidermidis growth can be achieved by strain-specific Lactobacillus
supplementation. Indeed, it has been reported that L. brevis DSM17250 secrets a peptide that stimulates
proliferation of S. epidermidis. As a result, L. brevis DSM17250 supplementation may have indirect
antimicrobial effects on skin pathogens [43]. Other probiotic strains have been reported to inhibit
P. acnes directly. Results from in vitro experiments showed that strains L. casei NCFB 161, L. acidophilus
NCFB 1748, L. plantarum DSM 12028, L. gasseri NCFB 2233, and Lactococcus lactis NCIMB 6681 exerted
antimicrobial effects against P. acnes, which were enhanced when combined with prebiotics [44].
Similarly, Lactococcus sp. HY 449 produced a bacteriocin that was effective in limiting the pathogen
in vitro and when applied topically in human patch tests [45].
Probiotic supplementation could also be employed for the alleviation of inflammation, a key
aspect of acne onset. In one study, the probiotic strain Escherichia coli Nissle 1917 was administered
orally to patients with acne and other intestinal-borne dermatoses. After the intervention period,
the probiotic group had normal immunoglobin-A (IgA) counts, decreased proinflammatory cytokines
levels, and normalized gut function. In addition, the skin lesions were significantly smaller or fully
recovered [46]. Insulin signaling is a determining factor in post-adolescence acne vulgaris onset. Insulin,
insulin-like growth factor-1 (IGF-1), and defective nuclear transcription factor forkhead box protein
O1 (FOXO1) promote acne by stimulating sebaceous lipogenesis and androgen signaling. According
to a recent clinical study, consumption of L. rhamnosus SP1 for 12-weeks led to decreased IGF-1 and
increased FOXO1 gene expression that ultimately resulted in alleviation of acne manifestations in
adult patients [47].
3.2. Psoriasis and Atopic Dermatitis
Chronic inflammation is a crucial factor for the development of autoimmune diseases. Specifically,
pathological T-cells that reside on the skin of psoriatic patients overproduce IL-17 in response
to IL-23, triggering the production of pro-inflammatory mediators IL-1β, IL-6, IL-8, TNF-α, and
chemoattractants from keratinocytes. These signaling molecules sustain chronic skin inflammation and
cause epidermal hyperplasia, the main trait of psoriatic plaques [48]. A novel therapeutic approach
to tackle skin auto-immune diseases could be the utilization of immunomodulatory probiotic strains.
In this vein, a BALB/c mice psoriasis model was used to evaluate the therapeutic potential of L. pentosus
GMNL-77. Following application of this probiotic strain on skin lesions, pro-inflammatory cytokines
were downregulated, the spleen size and differentiation of T-cells were decreased, and erythema
and inflammation signs were alleviated [49]. In the same context, psoriasis patients that consumed
B. infantis 35624 exerted a decrease in the proinflammatory markers IL-6, TNF-α, and serum CRP.
These effects could be attributed to the probiotic-induced proliferation of Tregs. However, these
findings were not directly linked to distinct clinical improvement [50]. Finally, in a clinical study
investigating the beneficial effects for skin lesions of probiotics in patients with inflammatory bowel
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disease, a reduction of psoriasis skin lesions occurrence was observed in patients that consumed VSL#3,
a probiotic preparation of eight live freeze-dried bacterial species [51].
Atopic dermatitis (AD) is the result of a Th1/Th2 leukocyte population imbalance that leads to
excessive mast cell degranulation and a Th2-mediated allergic response. Phenotypically, this translates
to skin erythema, hemorrhage, and itching that could be triggered by both genetic and environmental
factors. Most of the studies on the alleviation of AD focus on two parameters; inflammation and
the composition of gut and skin microbiota. Several studies on AD have employed probiotic strains
that exhibit anti-inflammatory properties. Kim et al., administered a probiotic mixture of L. casei,
L. plantarum, L. rhamnosus, B. lactis, and sodium butyrate to BABLB/c mice per os, following their
sensitization with whey protein [52]. It was demonstrated that probiotic supplementation switched
T cell differentiation towards Th1 and Treg populations and concomitantly, the microbiota composition
was altered favoring the reduction of type I hypersensitivity [52]. Similarly, L. plantarum IS-10506
attenuated the levels of specific inflammation markers, such as IL-4, IL-17, and interferon-γ (IFN-γ),
and increased the expression of immunomodulatory factors Forkhead box P3 (Foxp3+) and IL-10 in
BALB/c mice, as well as in pediatric AD patients that had orally received this probiotic strain. These
changes were accompanied by reduction in the Scoring Atopic Dermatitis Index (SCORAD) [53].
A significant decrease in Th2-mediated inflammatory responses and SCORAD scores were also
induced by oral L. acidophilus L-92 administration on adult AD patients [54]. In the same context, the
consumption of L. salvarius LA307 and L. rhamnosus LA305 inhibited skin inflammation in hairless
SKH-1 mice and constituted a decrease in hyperplasia, immune cell skin infiltration, and hyperkeratosis,
suggesting their potential benefits for AD patients [55]. Lactococcus chungagensis CAU 28T, a probiotic
derived from activated sludge, displayed anti-inflammatory, anti-allergic, and anti-bacterial properties
that lowered the molecular markers of AD and attenuated its clinical manifestations on NC/Nga
mice, an inbred AD murine model, that were fed with this strain [56]. Similarly, oral administration of
tyndallized and freeze-dried L. rhamnosus ICDD 3201 on Nc/Nga mice lowered IgE counts, resulting
in the neutralization of AD symptoms [57].
AD skin lesions are frequently colonized by high loads of S. aureus. Therapeutic interventions
limiting this pathogenic population result in clinical improvement of skin manifestations. It has been
shown that L. johnsonii NCC 533 promoted the expression of antimicrobial peptides and inhibited
adhesion of S. aureus to a reconstructed human epidermis (RHE) model in vitro [58]. In this text,
S. aureus-positive AD patients who participated in an open-label multicenter study experienced
improvement of lesion skin appearance after topical application of a lotion containing heat-treated
L. johnsonii NCC 533 cells. Such a positive outcome was linked to the reduction of S. aureus
population [59].
3.3. Chronic Conditions and Non-Healing Wounds
Non-healing wounds are a threat to diabetics, the elderly, the obese, and patients with chronic burn
wounds. When applied topically, probiotics either selectively exclude pathogenic microorganisms (that
deteriorate the wounds) or induce re-epithelization and collagen formation. In this light, researchers
engineered a patch containing nitric oxide gas-producing L. fermentum 7230 and tested it on infected and
ischemic rabbit wounds, assessing its wound-healing potential. Indeed, increased collagen synthesis
and blood flow to the wounds was recorded [60]. Probiotic strains that reportedly induce keratinocyte
migration and proliferation are LGG and L. reuteri, [61]. In addition, it has been shown that LGG
enhanced tight-junction barrier function of human primary keratinocytes by inducing the increase of
tight-junction protein levels of claudin 1, occludin, and ZO-1 [62]. Probiotic strains with antimicrobial
properties contribute positively to the management of chronic wounds. In this context, probiotics that
adhere to keratin exhibited antimicrobial properties against E. coli, P. acnes, and Pseudomonas aeruginosa.
Furthermore, the same strains inhibited early biofilm formation without affecting mature biofilms
in vitro [63]. In addition, S. aureus colonization could be combated by strain-specific application of
LGG [64], as well as from skin commensals S. epidermidis [65] and S. hominis [66].
Nutrients 2019, 11, 788 8 of 26
3.4. Aging Skin
Aging skin is characterized by increased pH, oxidative stress, and matrix metalloprotease activity
that translate in wrinkle formation, dehydration, and discoloration. Accumulating preclinical and
clinical evidence suggests that probiotics could potentially counteract phenotypic skin alterations,
restore stratum corneum flexibility, and enhance hair quality after local or oral administration [67].
Environmental factors, such as Ultra-Violet (UV) irradiation, accelerate skin aging through skin
dehydration and wrinkle formation. Probiotics appear to have regenerative effects on UV-induced
photodamaged skin. Oral administration of L. acidophilus reduced wrinkle formation caused by UVB
irradiation in a mouse model [68], while Bifidobacteria breve B-3 supplementation restored skin hydration
and reversed tight junction and basal membrane photodamage [69]. In this context, Bouilly-Gauthier
et al., investigated the ability of a supplement containing L. johnsonii and carotenoids to reverse early
UV-induced photodamage in healthy women. The intervention was beneficial, as it restored the
responses of the skin immune system [70]. Alternatively, other interventions were aimed toward the
activation of the endogenous, protective mechanisms. For example, Vitreoscilla fuliformis altered the
expression of a mitochondrial oxide dismutase, thus reducing UV-induced oxidative stress in vitro [71].
Another study reported that fermented acanthopanax koreanum root extract from L. plantarum and B.
bifidum had anti-senescence and anti-oxidant effects on human skin fibroblast cells, greater than the
non-fermented extract. The treated fibroblasts exhibited reduced expression of p53 and p21Cip1/WAF1
cell cycle proteins, and of matrix metalloproteinases, MMP-1, and MMP-3. These effects were
mediated by the probiotic-induced activation of the mitogen-activated protein kinase (MAPK) signaling
pathway [72]. Lastly, probiotics can be used for skin rehabilitation after cosmetic procedures. Fractional
CO2 laser resurfacing treatments are used to reduce the signs of aging, but have an unpleasant healing
process that includes inflammation, edema, erythema, and crusting. Post-operatively, the patients
need to apply, topically, broad-spectrum antibiotics, sunscreen, and hyaluronic acid masks, though
none of these alleviate inflammation [73]. Zoccali et al., employed CERABEST™, a cream that contains
probiotic-derived compounds and recorded a statistically significant reduction of postoperative skin
inflammation and swelling after topical application on the treated areas. However, probiotics have
minimal compatibility with other components of skin creams. Moreover, they can be used only for a
few days after production, as there is a rapid decline of their organoleptic properties. This is the main
reason that to date, there is not any functional skin care product available in the market for commercial
use [74]. A summary of the clinical studies investigating the beneficial effects of probiotics on skin
disorders is presented in Table 2.
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Table 2. Summary of clinical trials investigating the beneficial effects of probiotics on skin disorders.
Probiotic Strain Type of Study Regimen Findings Clinical Outcomes Reference
B. longum
66 female volunteers with reactive skin
participated in a randomized, double-blind,
placebo-controlled trial
Skin application, twice daily for
2 months ↓TEWL
Increased skin hydration and
resistance to physical aggression,
while limiting skin sensitivity
[41]
L. brevis DSM17250
30 volunteers with xerosis symptoms
participated in a randomized,
placebo-controlled, double blinded pilot
study
Skin application, twice daily for
4 weeks
↑Natural skin microbiota
↓DASI
↓TEWL
L. brevis supported the proliferation
of S. epidermidis, resulting in
symptom resolution
[43]
L. rhamnosus SP1
20 adult volunteers with acne participated in
a pilot, randomized, double-blinded,
placebo-controlled trial
Consumption of liquid supplement
once daily for 12 weeks,
3 × 109 CFU/day
↓IGF-1
↑FOXO1 Improvement in skin appearance [47]
B. infantis 35624
26 adult psoriasis patients and 36 healthy
volunteers participated in a randomized,
double-blind, placebo-controlled study
Oral administration, once daily for
6–12 weeks (1 × 1010 CFU)
↓CRP
↓TNF-α Systemic inflammation decrease [50]
L. plantarum IS-10506
22 children with mild and moderate AD
participated in a randomized, double-blind,
placebo-controlled trial
Oral administration, twice daily for
12 weeks (1010 CFU/day)
↓SCORAD
↑FOXP3+/IL-10
Th2 adaptive immune response was
suppressed resulting in clinical
improvement
[53]
L. acidophilus L-92
49 AD patients participated in a
double-blind, parallel-group,
placebo-controlled study
Oral consumption, once daily for
8 weeks
↓SCORAD
↓eosinophil count
↑TGF-β
Suppression of Th2-dominant
inflammation and clinical
improvement
[54]
L. johnsonii NCC 533 31 AD patients participated in an open-label,multicenter study
Local application, twice daily for
3 weeks
Stable S. aureus load
↓SCORAD
S. aureus colonization was controlled,
followed by local clinical
improvement of lesioned skin
[59]
DermaACB 62 consecutive patients with aged skin afterfractional CO2 laser treatment
Skin application, twice daily for
2 weeks
↓erythema, swelling
downtime
Post-operative inflammation signs
were reduced [74]
TEWL: trans-epidermal water loss; DASI: dry skin area and severity index; CFU: colony forming units; IGF-1: insulin-like growth factor-1; FOXO1: forkhead box protein O1; CRP: C-reactive
protein; TNF-α: tumor necrosis factor-α; AD: atopic dermatitis; SCORAD: scoring atopic dermatitis; FOXP3+: forkhead box protein P3; IL-10: interleukin-10; TGF-β: transforming growth
factor-β (↑: upregulation, ↓: downregulation).
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4. Probiotics and the Nervous System
Mood and behavior disorders may be caused by a chemical imbalance in the brain and are
directly linked to plasma corticosterone levels and deregulation of the hypothalamus-pituitary-adrenal
(HPA) axis. Neuroinflammation and autoimmunity provoke the onset of Alzheimer’s disease (AD),
Multiple Sclerosis (MS), and Parkinson’s disease (PD) by disrupting the blood-brain barrier or inducing
neuronal death. Conventional anti-depressants and anxiolytics have considerable side effects, while
current therapeutic interventions against neurodegenerative diseases have limited therapeutic efficacy.
Investigation and assessment of the potential of probiotics in preventing the symptoms or alleviating
comorbidities against these diseases have been the goals of several clinical studies (Table 3).
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Table 3. Summary of clinical trials investigating the effects of probiotics on neuronal health and disease.
Probiotic Strains Type of Study Regimen Findings Clinical Outcomes Reference
L. acidophilus, L. casei,
B. bifidum (viable and
freeze-dried)
40 patients with major depressive disorder
participated in a randomized, double-blind,
placebo-controlled trial
Once daily (capsule containing
2 × 109 CFU/g of each strain)
for 8 weeks
↓BDI, ↓serum insulin
↓HOMA-R, ↓hs-CRP
↑glutathione
Clinical improvement [75]
L. casei strain Shirota
35 chronic fatigue syndrome patients
participated in a randomized, double-blind,
placebo-controlled pilot study
Oral consumption, three times
daily for 8 weeks (8 × 109 CFU)
↑Lactobacillus, Bifidobacteria gut
populations, ↓anxiety
symptoms
Reduced anxiety symptoms [76]
L. helveticus R0052 and
B. longum R0175 55 healthy volunteers
Oral consumption, one stick per
day (3 × 109 CFU/stick) ↑HSCL-90 scale, ↑HADS, ↓UFC Psychological distress reduction [77]
B. longum 1714 22 healthy male volunteers participated in arepeated measures, placebo-controlled study
Oral administration, one stick
(1 × 109 CFU) each morning for
4 weeks
Changes in brain
electrophysiology (EEG profile)
Dampened stress responses and
improved memory [78]
L. casei strain Shirota
YIT 9029
49 healthy students participated in a
double-blind, placebo-controlled, and
parallel-group clinical trial
Daily consumption, 100
mL/day (1 × 1011 CFU/100
mL) for 8 weeks
↓VAS, ↓GSRS,
↓abdominal dysfunction score,
↑observed species
↑phylogenetic diversity
The onset of stress-associated
abdominal symptoms was
decelerated
[79]
B. bifidum R0071
655 healthy students participated in a
randomized, double-blind, placebo-controlled
study
One capsule per os (3 × 109
CFU) a day for 6 weeks
↓BSFS score, ↓self-reported
stress
The onset of stress-associated
abdominal symptoms was
decelerated
[80]
B. bifidum R0071 581 students participated in a randomized,double-blind, placebo-controlled study
One capsule per os
(3 × 109 CFU) a day for 7 weeks
↑Proportion of healthy days,
↓cold/flu episodes
The placebo group were less
likely to report a sick day [81]
L. brevis SBC8803
(SBL88™)
17 males with poor quality of sleep participated
in a non-randomized, double blind,
placebo-controlled and crossover pilot study
Oral administration, once daily
for 10 days (25 mg/day) ↑delta power value (µV
2/min) Sleep quality was increased [82]
L. rhamnosus HN001
423 women at 14–16 weeks gestation
participated in a randomized double-blind,
placebo-controlled trial
Oral administration, 6 × 109
CFU/day from enrollment to
6 months post-partum
↓EPDS, ↓STAI6 Lower post-partum depressionand anxiety scores [83]
L. acidophilus, L. casei,
B. bifidum, L. fermentum
60 patients with AD participated in a
randomized, double-blind and controlled trial
Oral consumption of 200
mL/day of fermented milk
(2 × 109 CFU/mL of each
probiotic) for 12 weeks
↑MMSE, ↓MDA, ↓hs-CRP
↓HOMA-B, ↑QUICKI
↓TG, ↓VLDL
Improved cognitive function [84]
L. acidophilus, L. casei,
B. bifidum, L. fermentum
60 MS patients participated in a randomized,
double-blind, placebo-controlled trial
Oral administration, once daily
for 12 weeks (capsules
containing 2 × 109 CFU/g of
each strain)
↓EDSS, ↓BDI, ↓DASS, ↓hs-CRP,
↓serum insulin
↓HOMA-R
Mental health improvement [85]
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Table 3. Cont.
Probiotic Strains Type of Study Regimen Findings Clinical Outcomes Reference
L. paracasei 24734,
L. plantarum 24730,
L. acidophilus 24735,
L. delbruckei bulgaricus
24734, B. longum 24736,
B. infantis 24737, B. breve
24732, S. thermophilus 2473
9 MS patients and 13 healthy volunteers
Oral administration, twice daily
for 2 months
(3.6 × 109 CFU/day)
↓KEGG pathway abundance
↑ CD8+T cells, ↑IL-10RA,
↑LILRB2, ↑CYBB ↓MALT1,
↓LGALS3
Reduced dysbiosis and
inflammation, a synergistic
effect with current medication
was observed and the
expression of MS-risk alleles
was decreased
[86]
L. acidophilus,
B. bifidum, L. reuteri,
L. fermentum
50 patients with PD participated in a
randomized, double-blind, placebo-controlled
pilot study
One capsule per os a day
(8 × 109 CFU) for 12 weeks
↓IL-1, ↓IL-8, ↓TNF-α, ↑TGF-β,
↑PPAR-γ N/A [87]
CFU: colony forming units; BDI: Beck depression inventory; HOMA-R: homeostasis model of assessment-estimated insulin resistance; hs-CRP: high-sensitivity C-reactive protein; HSCL-90:
Hopkins symptom checklist; HADS: hospital anxiety and depression scale; UFC: urinary free cortisol; EEG: electroencephalography; VAS: visual analogue scale; GSRS: gastrointestinal
symptom rating scale; BSFS: Bristol stool form scale; EPDS: Edinburgh postnatal depression scale; STAI: state trait anxiety inventory; AD: Alzheimer’s disease; MMSE: mini mental
state examination; MDA: malonaldehyde; MS: multiple sclerosis HOMA-B: homeostasis model assessment of β-cell function; QUICKI: quantitative insulin sensitivity check index; TG:
triglyceride; VLDL: very low density lipoprotein; EDSS: expanded disability status scale; DASS: depression anxiety and stress scale; KEGG: Kyoto encyclopedia of genes and genomes;
IL-10RA: interleukin-10 receptor; LILRB2: leukocyte immunoglobulin-like receptor subfamily B member 2; CYBB: cytochrome b beta chain; MALT1: mucosa-associated lymphoid tissue
lymphoma translocation protein 1; LGALS3: galectin-3; PD: Parkinson’s disease; IL-1: interleukin-1; IL-8: interleukin-8; TNF-α: tumor necrosis factor-α; TGF-β: tumor growth factor-β;
PPAR-γ: peroxisome proliferator-activated receptor gamma; N/A: Not Available (↑: upregulation, ↓: downregulation).
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4.1. Mood and Behavior Disorders
Stress- and depression-related behaviors are triggered by hormonal or neurotransmitter
imbalances, such as high blood corticosterone and reduced brain serotonin levels, respectively.
The effects of probiotics on these disorders are evaluated in preclinical animal models of chronic
stress and depression, such as maternally separated or restrained mice and rats. Maternal separation is
a strong early life stressor that disrupts the hypothalamus-pituitary-adrenal (HPA) axis, deregulating
major physiological processes, such as stress response, gut function, and immunity. Two commercially
available Lactobacillus strains, L. rhamnosus R0011 and L. helveticus R0052, were tested for their
potential to restore the activity of HPA axis in maternally separated rat pups. After a 20-day dose
regimen, plasma corticosterone (an indicator of the HPA axis function) was decreased to basal
levels. Subsequently, the alteration of corticosterone concentration resulted in the alleviation of
stress-related behaviors [88]. Likewise, supplementation of C57B1/6 male breast-fed, maternally
separated mice with Bifidobacterium pseudocatenulatum CECT 7765 reduced blood corticosterone levels.
In addition, this early-life probiotic intervention lowered stress-induced intestinal inflammation and
gut hyper-catecholaminergic activity, exhibiting long- and short-term outcomes in brain biochemistry
throughout the adult life of mice [89]. Chronic restraint models are employed to study depression
and chronic stress. To this end, depressive and anxiety behavior was investigated in Sprague-Dawley
(SD) rats after 21-day restraint regimens that were either exposed to L. helveticus NS8 or citalopram
(an antidepressant drug). The rats that consumed the probiotic strain exhibited decreased incidence
of chronic depression compared to those that consumed citalopram, as evidenced by behavioral
assays. These findings were attributed to the (i) probiotics-mediated regulation of hormonal responses,
(ii) increase of the anti-inflammatory interleukin, IL-10, and (iii) restoration of catecholamines and
brain-derived neurotrophic factor (BDNF) levels in the hippocampus [90]. Anxiety alleviation, learning,
and memory enhancement of anxious-born adult male BALB/c mice after probiotic supplementation
with B. longum 1714 and B. breve 1205 was evaluated in a series of behavioral tests [91,92]. It was
shown that the two strains resulted in different outcomes. Specifically, B. longum 1714 induced
anti-depressant like behaviors together with better learning and memory, while B. breve 1205 alleviated
anxiety behaviors. Nonetheless, no significant changes in corticosterone levels were observed after
either intervention [91,92]. In a clinical study, major depressive disorder patients consumed a probiotic
capsule containing freeze-dried L. acidophilus, L. casei, and B. bifidum for 8 weeks. At the end of the
intervention, the probiotics group showed reduced inflammation and oxidative stress and experienced
positive clinical outcomes [75].
Anxiety triggered by imbalances in serotonergic activity results in obsessive-compulsive disorder
(OCD) phenotype. BALB/c mice that were pretreated with LGG before induction of the OCD
phenotype did not exhibit OCD-like behaviors in behavioral testing. The beneficial outcomes of
this intervention could be attributed to anxiety alleviation rather than to restoration of the neurological
mechanisms implicated in OCD-onset. In this context, LGG could be administered alone or in
combination with fluoxetine, an anti-depressant used for human OCD symptom alleviation [93].
Chronic fatigue syndrome (CFS) is a multifactorial disease with a wide spectrum of manifestations,
many of which correlate to gut microbiota composition and function. In a clinical study, CFS patients
experienced alleviation of anxiety symptoms after the consumption of L. casei strain Shirota (LcS).
In addition, the participants’ microbiota was enriched with Lactobacillus and Bifidobacteria species
post-treatment [76].
Studies have shown that probiotic consumption could protect predisposed individuals from
chronic anxiety and depression. In this line, the efficacy of L. helveticus R0052 and B. longum R0175
was tested on healthy human volunteers. The volunteers’ clinical mental state was evaluated by
global scores of hospital anxiety and depression scale (HADs), and the global severity index of the
Hopkins symptoms checklist (HSCL-90). A positive score of mental health was recorded that was
linked to changes in the hormonal state. Particularly, urinary free cortisol was reduced, indicating
a visible effect on the host’s physiology. In addition, these strains exhibited anti-inflammatory
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properties, which might reflect the normalization of hormonal responses [77]. A clinical study showed
that B. longum 1714 consumption improved cognitive performance, alleviated stress, and enhanced
visuospatial memory and frontal midline mobility of healthy human adults by changing electrical
brain activity, as recorded by electroencephalography (EEG) [78]. Likewise, the consumption of a
mixture of probiotics (B. animalis, Streptococcus thermophiles, L. bulgaricus, and L. lactis) changed the
brain electrical pattern in healthy female volunteers, as evaluated by functional magnetic resonance
imaging (fMRI). The probiotics group exhibited decreased activity in the somatosensory cortex, the
insula, and the periaqueductal faces after viewing emotionally evocative faces or scenes. This translates
to a different emotional response compared to the placebo group [94]. Furthermore, probiotics with
anxiolytic properties could be consumed by healthy individuals throughout stressful periods with
beneficial effects. In this regard, in a clinical study, a number of students were recruited before their
school exams to evaluate the anxiolytic potential of LcS. The participants consumed fermented milk
containing LcS or placebo for 8 weeks before exams. LcS alleviated stress-induced changes in leukocyte
gene expression and abdominal dysfunction. The mental state of the subjects was evaluated on the
visual analogue state (VAS), and by measuring salivary cortisol 1 day before examination, which
peaked only in the placebo group. Apart from alleviating visceral pain and abdominal symptoms, LcS
suppressed the proliferation of the Bacteroidaceae family, which is oftentimes observed in IBS patients,
and increased α-diversity, a marker of microbial community diversity that is linearly correlated to
the balance of the gut microecosystem [79]. Other studies have demonstrated that probiotic strains
limit anxiety manifestations, such as gut dysfunction [80], flu-like symptoms [81], and insomnia [82],
as well as post-partum depression and anxiety [83] (see Table 3 for more details). Lastly, the possible
effects of probiotic supplementation on the mental state of professional athletes were described in
a recent systematic review. Exercise-induced stress behaviors are triggered by the psychological
pressure of competitive athleticism and are possibly side-effects of a diet based on low consumption of
plant-polysaccharides (that athletes are usually subjected to). This diet is associated with reduced gut
microbiota diversity and functionality, causing deregulation of the HPA axis. It was suggested that a
balanced diet containing pro- and prebiotics is capable of restoring microbiota structure and function,
resulting in the resolution of stress disorders in athletes [95].
4.2. Visceral Nociception
Visceral pain refers to a wide range of pain sensations in the abdominal area and it is most
prevalent among women. Nociceptors are scattered across the organs and communicate pain sensations
to the brain by activating certain neuronal circuits. The vagus nerve is widely accepted as the main
highway of signal transduction. In a recent study, Kaelberer et al., showed a direct connection between
enteroendocrine cells and vagal nodose neurons [96]. Nociceptors can be triggered by a variety
of stimuli, both endogenous and exogenous. Most of these stimuli, such as immune responses,
microbiota configuration, and parasympathetic activity may be manipulated by probiotics. In a
preclinical study, visceral hypersensitive Wistar-Kyoto (WKY) and visceral normosensitive SD rats
were fed with L. salivarius UCC118, B. infantis 35624, or B. breve UCC2003 to evaluate their pain
responses after colorectal distention. The rats exhibited increased pain threshold and decreased
pain behaviors following B. infantis 35624 administration. The changes in pain perception were
corticosterone-independent and did not affect rat behavior [97]. Rousseaux et al., showed that probiotic
treatment of colon adenocarcinoma cell lines, HT29, changed the expression of analgesic opioid
and cannabinoid receptors. Specifically, L. acidophilus NCFM and L. salivarius Ls-33 increased the
transcription of the opioid receptor gene, whereas only L. acidophulus NCFM managed to upregulate
expression of cannabinoid receptors [98]. To confirm the results in vivo, L. acidophulus NCFM cells
were administered to BALB/c and SD rats. Immunohistochemical analysis revealed that the probiotic
strain induced the expression of the analgesic receptors in gut epithelium. Conclusively, rats receiving
probiotic supplementation exhibited increased pain thresholds during colorectal distention [98].
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4.3. Neurodegenerative and Demyelinating Diseases
Alzheimer’s disease, Multiple Sclerosis, and Parkinson’s disease share a common immunological
basis. Chronic activation of the neuroimmune system, immunosenescense, and high levels of
circulating proinflammatory cytokines result in neuronal death and disruption of the blood-brain
barrier continuity, contributing to the manifestations of the diseases. Probiotics with anti-inflammatory
and anti-oxidant potential have been studied for their beneficial effects against neurodegenerative and
demyelinating disease onset, manifestations, and comorbidities.
Probiotics may decelerate AD onset and minimize its manifestations by suppressing brain
pro-inflammatory and oxidative responses, while improving cognition and memory. In this context, AD
male Wistar rats that received L. acidophilus, L. fermentum, B. lactis, and B. longum in tap water exhibited
decreased amyloid plaque size, and improved spatial memory, orientation, and mood. In addition,
malondialdehyde and superoxide dismutase reached optimal levels in the hippocampi, contributing
to the clearance of plaques. Interestingly, control rats did not exhibit any improvement in memory
and cognition, indicating that the use of the probiotic strains did not enhance neuronal function in
healthy animals [99]. Similarly, administration of SLAB51 probiotic formulation to transgenic AD mice
preserved brain physiological function by activating Sirtuin-1 (SIRT1)-related pathways [100]. SIRT1
is a NAD+-dependent protein deacetylase with established neuroprotective potential, as it reduces
ROS levels in the brain by activating superoxide dismutase 2 and catalase [101]. Probiotics targeting
neuroinflammation are also effective in alleviating AD manifestations. Oral administration of B. breve
A1 to AD mice prevented cognitive dysfunction and ameliorated neuronal inflammation through SCFA
production [102]. Interestingly, SCFAs stimulate glutamate signaling, resulting in the elevation of
brain γ-aminobutirc acid (GABA) levels [103]. Likewise, CFT-Swiss healthy male mice supplemented
with Enterococcus faecium CFR 3003 and LGG had increased cytosolic GABA and dopamine (DA)
levels [104]. More specifically, mice that consumed E. faecium CFR 3003 exhibited elevated DA
levels in the cortex, while mice supplemented with LGG showed higher concentrations of DA in
the striatum. E. faecium CFR 3003 induced the production of GABA in every brain region investigated
(cortex, hippocampus, and striatum), whereas LGG elevated GABA levels only in the hippocampus.
The changes in neurotransmitter levels were accompanied by the induction of anti-oxidant and
anti-inflammatory state. The fact that post-mortem AD patient brain biopsies reveal decreased GABA
levels underlines the protective nature of this inhibitory neurotransmitter against AD onset [104].
In the same fashion, hippocampal acetylocholine (Ach) decelerates AD onset. L. plantarum MTCC
stimulated Ach production in the hippocampus and cerebral cortex and reversed histopathology
features in AD Wistar rats. These cellular changes resulted in improvement of behavior and learning
skills [105]. To date, only one clinical trial has been performed to investigate the outcomes of probiotic
administration to AD patients. In this study, the participants consumed either plain milk or milk
enriched with L. acidophilus, L. casei, B. bifidum, and L. fermentum for 12 weeks, and the results were
evaluated based on the mini-mental state examination (MMSE) scores and the concentration of related
plasma biomarkers. The group that consumed probiotics had significantly improved MMSE scores
and favorable changes in malondialdehyde and hs-CRP levels, markers of insulin metabolism, and
serum triglyceride and very low-density lipoprotein (VLDL) levels. On the other hand, markers of
inflammation, oxidative stress, and other lipid profiles remained unchanged [84].
Several studies conducted on murine MS models showed that administration of monospecies [106,
107], mixtures [108,109], heat-killed strains [110], or genetically modified probiotics [111] provoke
specific immunomodulatory effects. Most of the utilized strains switched T cell differentiation towards
Tregs and up-regulated the production of the anti-inflammatory cytokine IL-10, while down-regulating
the expression of the pro-inflammatory cytokines IL-17 and IL-6, both at the periphery and on
site. Overall, blocking of inflammation strengthened the gut barrier and decreased the incidence
of autoimmunity, while the activation of Tregs attenuated MS symptoms and progression. These
positive results were recapitulated in clinical studies. A probiotic capsule containing L. acidophilus,
L. casei, L. fermentum, and B. bifidum positively affected mental health and disability scores, glucose
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and lipid metabolism, and inflammation in MS patients [85]. Another study compared changes on
the expression of immune related genes in healthy volunteers and MS patients after consumption of
probiotics. MS patients who received the probiotic mixture containing Lactobacilli, Bifidobacteria, and
Streptococci strains exhibited decreased expression of CD80 on monocytes and of HLA-DR MFI on
dendritic cells. Likewise, the probiotic-treated healthy volunteers had lower expression of the MS risk
allele HLA-DQ1. The populations of Th1 and Th17 were reduced in both the controls and MS patients,
while memory CD8+ T populations were increased and LAP+ Tregs were decreased exclusively on
MS patients and controls, respectively. However, these findings were not correlated with clinical
improvement [86].
So far, the direct effects of probiotics on Parkinson’s disease-related motor dysfunction have
been poorly investigated. Most of the clinical studies investigating probiotic actions in PD have
focused on the reduction of its comorbidities, one of which is gut dysfunction that stems, mainly,
from enteric neuronal damage and intestinal inflammation. Indeed, Houser et al., confirmed the
presence of inflammation biomarkers in PD patients’ stools [112]. In this context, a recent study
assessed the anti-inflammatory potential of L. acidophilus, B. bifidum, L. reuteri, and L. fermentum
on PD patients. The probiotic mixture dampened inflammatory responses by suppressing the
expression of IL-1, IL-8, and TNF-α in peripheral blood mononuclear cells (PBMC) and upregulating
the expression of transforming growth factor-β (TGF-β) in the same cellular subset [87]. The decrease
of gut inflammation could potentially reflect the normalization of gut functionality. In this context,
consumption of fermented milk containing multiple probiotic strains and prebiotic fiber was superior
to placebo in improving constipation in patients with PD [113]. Furthermore, L. acidophilus and
B. infantis supplementation resolved abdominal pain and bloating in similar levels to trimebutine, a
drug commonly used to restore normal bowel function [114].
5. New Directions in Probiotic Research
Probiotics are thought to exert strain-specific health promoting actions. Indeed, it has been
reported that strains of the same species induce differential effects on host physiology. A recent
metanalysis of preclinical and clinical data concluded that Lactobacillus and Saccharomyces treatments
exhibit variable results and efficacy on the alleviation of antibiotics-associated diarrhea and IBS
symptoms, largely depending on the strain used [115]. Therefore, probiotic research should follow
a case-by-case approach when examining the beneficial actions of specific strains on human health.
In addition, according to preclinical studies, gender and person-specific traits (such as sexual
dimorphism in immune responses and gut microbiota composition) define the success of probiotic
supplementation. For instance, administration of L. reuteri BM36301 to male and female murine models
of aging resulted in reduction of inflammation and in enhancement of skin health exclusively in female
mice [40]. Similarly, female Wistar rats that consumed Lactobacillus farciminis exhibited reduced gut
inflammation and visceral analgesia, while male rats did not experience these beneficial effects [116].
Gender-specific microbiota composition affects the central nervous system (CNS) serotonergic activity,
resulting in differential anxiety manifestations in mice. Probiotics also appear to regulate tryptophan
availability [117], a serotonin precursor, only in male germ-free mice [118]. Similarly, L. reuteri 6475
exerts beneficial effects on bone health of female osteoporotic mice after a mild inflammatory status is
induced [119].
In an elegant study, Suez et al., recently showed that human microbiota exert a person-specific
probiotic colonization resistance profile. Healthy human volunteers that consumed a mixture of 11
commercially-available probiotic strains exhibited differential permissibility to probiotic colonization.
Considering differences in absolute abundance of strains in the gut after probiotics administration,
participants were clustered into colonization permissive and resistant individuals. The bioinformatic
analysis of tissue and mucosal samples acquired by colonoscopy and gastroscopy revealed that
probiotic gut colonization is not binary; rather it varies greatly among the permissive volunteers.
The person-specific results were attributed to two factors:—permissive individuals had lower levels of
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probiotic commensals and decreased activity of immune-related pathways in their gut. Particularly,
these pathways were linked to innate and adaptive immune responses. Interestingly, both groups
of permissive and resistant individuals exhibited a “steady washout” of probiotic strains during the
intervention, so stool microbiota is not representative of gut colonization. These findings pave the way
for personalized probiotics [120].
In this direction, the first phase of Human Microbiome Project (HMP), which was completed in
2013, managed to characterize a core healthy human skin, gastrointestinal, and urogenital microbiota
structure and function by utilizing robust, high through-put sequencing techniques and bioinformatics
tools [121,122]. The second phase of the project, the integrative HMP (iHMP), is ongoing and aims at
deciphering the role of microbiota in health and disease. Particularly, iHMP investigates the link of
microbiota to preterm birth, the onset of IBD, and type-II diabetes. Accumulating evidence reveals
the concurrence of microbiota structural and functional imbalances, termed as dysbiosis, with the
onset of common, bone [123], skin [124], and nervous system disorders [125]. The host’s genetic
makeup could also be considered as a dysbiosis risk factor [126,127]. Genome-wide association studies
revealed 58 single nucleotide polymorphisms (SNPs) that are associated with the relative abundance
of specific taxa [128] and 33 SNPs were associated with specific microbial pathways [129]. These
polymorphisms are located in loci, which are implicated in variations in the vitamin D receptor [130],
in immune-related pathways, such as JAK/STAT signaling, chemokine signaling, C-X-C chemokine
receptor type-4 (CXCR4) and pattern recognition receptor (PRR) signaling, as well as in melatonin and
leptin signaling, inositol phosphate metabolism, gonadotropin-releasing hormone (GnRH) signaling
pathway, bile acid synthesis, and sulfide oxidation to sulfate [131].
Fecal-Microbiome Transplant (FMT) is gaining momentum in precise microbiota alteration.
The first successful application of FMT rehabilitated the gut microbiome post-antibiotic treatment
and inhibited Clostridium difficile colonization [132]. Notably, a recent study showed that FMT is a
more effective approach in post-antibiotics microbiota structural and functional reconstitution than
probiotics. Lactobacillus probiotic strains inhibit the proliferation of commensals by secreting yet-to
be characterized inhibitory compounds [133]. FMT could be applied as an alternative therapy to
other non-infectious extraintestinal diseases [134]. In this context, a clinical study has shown that
FMT from lean donors to patients with metabolic diseases reversed the pathogenic phenotype [135].
Similarly, Kragsnaes et al., have proposed recently a working protocol to investigate the effects of FMT
from healthy donors to people suffering from psoriatic arthritis [136]. Gut microbiota also regulates
patients’ response to chemotherapy and immunotherapy. To this aim, the donation of the microbiota
of responsive patients to non-responders is expected to increase therapy success [137]. Skin microbiota
transplantation could also be useful for alleviating skin conditions [138]. In an attempt to establish
a successful protocol for skin microbiome transplantation in patients suffering from skin disorders,
Perin et al. managed to successfully transplant forearm microbiota to the back of participants with
long-lasting effects being observed in two out of four volunteers [139].
Appropriate delivery is a crucial factor for probiotic efficacy. To observe direct effects on skin
lesions, probiotics need to be applied topically. A major limitation in this approach is that live
probiotics are not compatible to other components of creams, resulting in a rapid organoleptic decline.
To combat this limitation, probiotic research has been redirected to the investigation of the properties
of cell-free supernatants (CFS) and inactivated strains, termed as “paraprobiotics” [140]. Certain
paraprobiotics exert anti-microbial, anti-inflammatory, and anti-aging actions, while being stable in
preparations [41,58,59]. Similarly, beneficial outcomes have been reported in preclinical models of bone
and CNS pathophysiology after CFS or heat-killed probiotics treatment. In this regard, heat-killed
Lactococcus lactis cremonis H61 protected senescence-accelerated mice from bone loss and aging skin
manifestations [141] and heat-killed Pediococcus acidilactici R057 induced immunomodulatory results
against a preclinical model of multiple sclerosis [110]. Additionally, several studies have reported
the anti-proliferative potential of Lactobacillus casei CFS in vitro [142,143]. Konishi et al., managed to
isolate and characterize ferrichrome, the active component in this preparation, and compared its action
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to the established anti-cancer drugs, 5-fluorouracil and cisplatin. Notably, ferrichrome exhibited a
better anti-proliferative activity than the anti-cancer drugs, and the authors proposed that this active
compound of probiotic origin could be utilized to halt colon carcinoma progression [143]. Importantly,
sterile CFS and its isolated components make probiotic supplementation accessible to the vulnerable
populations of immunocompromised or immunodeficient individuals, to whom live microorganism
consumption is not advised.
Finally, dietary components, such as prebiotic fibers, could enhance the efficiency of probiotic
supplementation. The most commonly used prebiotics are non-digestible complex carbohydrates,
such as fructooligosaccharides (FOS), galactoologisaccharides (GOS), and inulin. Prebiotics can be
utilized as carbon sources for primary or secondary metabolism of specific gut commensals and
probiotics [144]. Their beneficial effects on human physiology mainly stem from their ability to induce
taxonomic and metabolic shifts in the gut microbial communities. The combinatory administration
of prebiotic fibers and probiotic strains, termed as “synbiotics”, most frequently includes mixtures
of Lactobacilli or Bifidobacteria strains admixed with FOS or inulin [145]. However, a limited number
of clinical trials have evaluated the effect of synbiotics on human health and disease, and so far, no
specific guidelines have been established for their use.
6. Conclusions
Probiotic supplementation aiming at the attenuation of extraintestinal pathological conditions is a
promising novel therapeutic approach. However, lack of consistency of the outcomes observed between
animal and clinical studies attributed to the differences in gut microbiota composition represents a
major hurdle that hinders the clinical application of probiotic strains. Thus, carefully designed
protocols for probiotic use that consider strain-, host-, and sex- specificity of their action and optimal
route for their administration could maximize their efficacy. In this line, the characterization of the
human-microbiome interactome has set the pace for targeted interventions. Whether probiotics or FMT
are more potent in microbiota reconstitution is still under debate. Nonetheless, both approaches could
potentially benefit people suffering from common disorders, such as osteoporosis, non-healing wounds
and autoimmune skin illnesses, mood, behavior, memory, and cognitive impairments. The latest trend
in probiotic research, next-generation probiotics, goes beyond traditional terminology and includes
microorganisms with beneficial actions that are not members of the commonest probiotic genera,
Lactobacillus and Bifidobacteria. These microorganisms could be utilized in drug discovery, but not for
the production of foodstuffs [146]. The significant technological advancements of the last decade have
accelerated the understanding of microbiota- and probiotic-induced effects on the host. The translation
of this knowledge in clinical practice is expected to flourish in the years to come.
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